| 1 |
Couderc AL, Liuu E, Boudou-Rouquette P, Poisson J, Frelaut M, Montégut C, Mebarki S, Geiss R, Ap Thomas Z, Noret A, Pierro M, Baldini C, Paillaud E, Pamoukdjian F. Pre-Therapeutic Sarcopenia among Cancer Patients: An Up-to-Date Meta-Analysis of Prevalence and Predictive Value during Cancer Treatment. Nutrients 2023;15. [PMID: 36904192 DOI: 10.3390/nu15051193] [Reference Citation Analysis]
|
| 2 |
Ge C, Huang X, Zhang S, Yuan M, Tan Z, Xu C, Jie Q, Zhang J, Zou J, Zhu Y, Feng D, Zhang Y, Aa J. In vitro co-culture systems of hepatic and intestinal cells for cellular pharmacokinetic and pharmacodynamic studies of capecitabine against colorectal cancer. Cancer Cell Int 2023;23:14. [PMID: 36717845 DOI: 10.1186/s12935-023-02853-6] [Reference Citation Analysis]
|
| 3 |
Nara K, Yamamoto T, Sato Y, Yagi K, Kawasaki K, Toriumi T, Takada T, Seto Y, Suzuki H. Low pretherapy skeletal muscle mass index is associated with an increased risk of febrile neutropenia in patients with esophageal cancer receiving docetaxel + cisplatin + 5-fluorouracil (DCF) therapy. Support Care Cancer 2023;31:150. [PMID: 36737558 DOI: 10.1007/s00520-023-07609-6] [Reference Citation Analysis]
|
| 4 |
Lee J, Cho JR, Kim DW, Yang IJ, Suh JW, Oh HK, Kang SB. Clinical impact of preoperative and postoperative sarcopenia on oncological outcomes in non-metastatic colorectal cancer. Colorectal Dis 2022. [PMID: 36461667 DOI: 10.1111/codi.16439] [Reference Citation Analysis]
|
| 5 |
Gu YJ, Chen LM, Gu ME, Xu HX, Li J, Wu LY. Body mass index-based predictions and personalized clinical strategies for colorectal cancer in the context of PPPM. EPMA J 2022;13:615-32. [PMID: 36505896 DOI: 10.1007/s13167-022-00306-0] [Reference Citation Analysis]
|
| 6 |
Martin P, Botsen D, Brugel M, Bertin E, Carlier C, Mahmoudi R, Slimano F, Perrier M, Bouché O. Association of Low Handgrip Strength with Chemotherapy Toxicity in Digestive Cancer Patients: A Comprehensive Observational Cohort Study (FIGHTDIGOTOX). Nutrients 2022;14. [PMID: 36364711 DOI: 10.3390/nu14214448] [Reference Citation Analysis]
|
| 7 |
Wan Q, Yuan Q, Zhao R, Shen X, Chen Y, Li T, Song Y. Prognostic value of cachexia index in patients with colorectal cancer: A retrospective study. Front Oncol 2022;12:984459. [DOI: 10.3389/fonc.2022.984459] [Reference Citation Analysis]
|
| 8 |
Gong C, Wan Q, Zhao R, Zuo X, Chen Y, Li T. Cachexia Index as a Prognostic Indicator in Patients with Gastric Cancer: A Retrospective Study. Cancers (Basel) 2022;14. [PMID: 36139560 DOI: 10.3390/cancers14184400] [Reference Citation Analysis]
|
| 9 |
Jang MK, Park S, Park C, Doorenbos AZ, Go J, Kim S. Body composition change during neoadjuvant chemotherapy for breast cancer. Front Oncol 2022;12:941496. [DOI: 10.3389/fonc.2022.941496] [Reference Citation Analysis]
|
| 10 |
Beukers K, Voorn M, Trepels R, van de Wouw A, Vogelaar F, Havermans R, Janssen-heijnen M. Associations between outcome variables of nutritional screening methods and systemic treatment tolerance in patients with colorectal cancer: A systematic review. Journal of Geriatric Oncology 2022. [DOI: 10.1016/j.jgo.2022.06.010] [Reference Citation Analysis]
|
| 11 |
de Jong C, Chargi N, Herder GJM, van Haarlem SWA, van der Meer F, van Lindert ASR, Ten Heuvel A, Brouwer J, de Jong PA, Devriese LA, Huitema ADR, Egberts TCG, de Bree R, Deneer VHM. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle 2022;13:1554-64. [PMID: 35301821 DOI: 10.1002/jcsm.12967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 12 |
Meyer H, Strobel A, Wienke A, Surov A. Prognostic role of low-skeletal muscle mass on staging computed tomography in metastasized colorectal cancer: a systematic review and meta-analysis. Clinical Colorectal Cancer 2022. [DOI: 10.1016/j.clcc.2022.03.005] [Reference Citation Analysis]
|
| 13 |
Graca FA, Rai M, Hunt LC, Stephan A, Wang Y, Gordon B, Wang R, Quarato G, Xu B, Fan Y, Labelle M, Demontis F. The myokine Fibcd1 is an endogenous determinant of myofiber size and mitigates cancer-induced myofiber atrophy. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-30120-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Smit D, Mols F, Bonhof CS, Bours MJL, Vreugdenhil G, Beijer S. Is CT-based body composition associated with long-term chemotherapy-induced peripheral neuropathy in colorectal cancer survivors? Support Care Cancer 2022. [PMID: 35416503 DOI: 10.1007/s00520-022-07036-z] [Reference Citation Analysis]
|
| 15 |
Commission for Hospital Hygiene and Infection Prevention (KRINKO). Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute. GMS Hyg Infect Control 2022;17:Doc07. [PMID: 35707229 DOI: 10.3205/dgkh000410] [Reference Citation Analysis]
|
| 16 |
Franco Valle K, Lubner MG, Pickhardt PJ. Computed Tomography Assessment of Sarcopenic Myosteatosis for Predicting Overall Survival in Colorectal Carcinoma: Systematic Review. J Comput Assist Tomogr 2022;46:157-62. [PMID: 35297571 DOI: 10.1097/RCT.0000000000001281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 17 |
da Silva Dias D, Machado M, Trabulo C, Gosálbez B, Ravasco P. Impact of Body Composition on Prognosis and Dose-Limiting Toxicities on Metastatic Colorectal Cancer. Front Nutr 2022;8:671547. [DOI: 10.3389/fnut.2021.671547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 18 |
Poulia KA, Antoniadou D, Sarantis P, Karamouzis MV. Pancreatic Cancer Prognosis, Malnutrition Risk, and Quality of Life: A Cross-Sectional Study. Nutrients 2022;14. [PMID: 35276801 DOI: 10.3390/nu14030442] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 19 |
Chargi N, Bashiri F, Wendrich AW, Smid EJ, de Jong PA, Huitema ADR, Devriese LA, de Bree R. Image-based analysis of skeletal muscle mass predicts cisplatin dose-limiting toxicity in patients with locally advanced head and neck cancer. Eur Arch Otorhinolaryngol 2022. [PMID: 35038029 DOI: 10.1007/s00405-021-07229-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 20 |
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH. Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy. Clinical Lung Cancer 2022. [DOI: 10.1016/j.cllc.2021.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Bruno KA, Sobreira da Silva MJ, Chaves GV. Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma. Acta Oncol 2021;60:1611-20. [PMID: 34634224 DOI: 10.1080/0284186X.2021.1983210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 22 |
Matsunaga T, Saito H, Miyauchi W, Shishido Y, Miyatani K, Morimoto M, Murakami Y, Hanaki T, Kihara K, Yamamoto M, Tokuyasu N, Takano S, Sakamoto T, Hasegawa T, Fujiwara Y. Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil. BMC Cancer 2021;21:1219. [PMID: 34774016 DOI: 10.1186/s12885-021-08953-8] [Reference Citation Analysis]
|
| 23 |
Gallois C, Bourillon C, Auclin E, Artru P, Lièvre A, Lecomte T, Locher C, Marthey L, Faroux R, Pernot S, Barret M, Taieb J. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. Clin Res Hepatol Gastroenterol 2021;45:101603. [PMID: 33662782 DOI: 10.1016/j.clinre.2020.101603] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 24 |
Han SR, Bae JH, Lee CS, Al-Sawat A, Park SJ, Lee HJ, Yoon MR, Jin HY, Lee YS, Lee DS, Lee IK. Serial measurements of body composition using bioelectrical impedance and clinical usefulness of phase angle in colorectal cancer. Nutr Clin Pract 2021. [PMID: 34609767 DOI: 10.1002/ncp.10754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 25 |
Yoon HG, Oh D, Noh JM, Cho WK, Sun JM, Kim HK, Zo JI, Shim YM, Kim K. Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer. J Cachexia Sarcopenia Muscle 2021;12:1144-52. [PMID: 34145771 DOI: 10.1002/jcsm.12747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 26 |
Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, Wienke A. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. Clin Nutr 2021;40:5298-310. [PMID: 34536638 DOI: 10.1016/j.clnu.2021.08.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 27 |
Christensen ME, Olsen PR, Haahr A, Rose HK, Norlyk A. Struggling to Eat to Survive Cancer-Lived Experiences of Eating Among Adolescents and Young Adults Undergoing High-Emetogenic Chemotherapy. J Adolesc Young Adult Oncol 2021. [PMID: 34424776 DOI: 10.1089/jayao.2021.0062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 28 |
Sheean P, Gomez-Perez S, Joyce C, O'Connor P, Bojko M, Smith A, Vasilopoulos V, Rao R, Sclamberg J, Robinson P. Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer. Breast Cancer Res Treat 2021. [PMID: 34389926 DOI: 10.1007/s10549-021-06358-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 29 |
van Rees JM, Hartman W, Nuyttens JJME, Oomen-de Hoop E, van Vugt JLA, Rothbarth J, Verhoef C, van Meerten E. Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. BMC Gastroenterol 2021;21:313. [PMID: 34348673 DOI: 10.1186/s12876-021-01886-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 30 |
Zhou X, Chang Y, Qian J, Shen C, Han J, Zhao H, Chang R. Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy. Med Sci Monit 2021;27:e929474. [PMID: 34330885 DOI: 10.12659/MSM.929474] [Reference Citation Analysis]
|
| 31 |
Haiducu C, Buzea A, Mirea LE, Dan GA. The prevalence and the impact of sarcopenia in digestive cancers. A Systematic Review. Rom J Intern Med 2021. [PMID: 34218540 DOI: 10.2478/rjim-2021-0026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 32 |
Drami I, Pring ET, Gould L, Malietzis G, Naghibi M, Athanasiou T, Glynne-Jones R, Jenkins JT. Body Composition and Dose-limiting Toxicity in Colorectal Cancer Chemotherapy Treatment; a Systematic Review of the Literature. Could Muscle Mass be the New Body Surface Area in Chemotherapy Dosing? Clin Oncol (R Coll Radiol) 2021:S0936-6555(21)00188-6. [PMID: 34147322 DOI: 10.1016/j.clon.2021.05.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 33 |
Molenaar-Kuijsten L, Jacobs BAW, Kurk SA, May AM, Dorlo TPC, Beijnen JH, Steeghs N, Huitema ADR. Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics. Cancer Med 2021;10:4781-9. [PMID: 34121365 DOI: 10.1002/cam4.4038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
Maddalena C, Ponsiglione A, Camera L, Santarpia L, Pasanisi F, Bruzzese D, Panico C, Fiore G, Camardella S, Caramia T, Farinaro A, De Placido S, Carlomagno C. Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study. World J Clin Oncol 2021; 12(5): 355-366 [PMID: 34131567 DOI: 10.5306/wjco.v12.i5.355] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 35 |
Wang J, Tan S, Wu G. Oral nutritional supplements, physical activity, and sarcopenia in cancer. Curr Opin Clin Nutr Metab Care 2021;24:223-8. [PMID: 33534418 DOI: 10.1097/MCO.0000000000000736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 36 |
Chargi N, Wegner I, Markazi N, Smid E, de Jong P, Devriese L, de Bree R. Patterns, Predictors, and Prognostic Value of Skeletal Muscle Mass Loss in Patients with Locally Advanced Head and Neck Cancer Undergoing Cisplatin-Based Chemoradiotherapy. J Clin Med 2021;10:1762. [PMID: 33919607 DOI: 10.3390/jcm10081762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 37 |
Líška D, Pupišová Z. The importance of physical activity and rehabilitation in patients with colorectal cancer. Onkologie 2021;15:30-34. [DOI: 10.36290/xon.2021.006] [Reference Citation Analysis]
|
| 38 |
Keaver L, Loftus A, Quinn L. A review of iPhone and Android apps for cancer patients and survivors: assessing their quality, nutrition information and behaviour change techniques. J Hum Nutr Diet 2021;34:572-84. [PMID: 33453133 DOI: 10.1111/jhn.12857] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 39 |
. Anforderungen an die Infektionsprävention bei der medizinischen Versorgung von immunsupprimierten Patienten : Empfehlung der Kommission für Krankenhaushygiene und Infektionsprävention (KRINKO) beim Robert Koch-Institut. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021;64:232-64. [PMID: 33394069 DOI: 10.1007/s00103-020-03265-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 40 |
Campelj DG, Timpani CA, Petersen AC, Hayes A, Goodman CA, Rybalka E. The Paradoxical Effect of PARP Inhibitor BGP-15 on Irinotecan-Induced Cachexia and Skeletal Muscle Dysfunction. Cancers (Basel) 2020;12:E3810. [PMID: 33348673 DOI: 10.3390/cancers12123810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 41 |
Shibata M, Fukahori M, Kasamatsu E, Machii K, Hamauchi S. A Retrospective Cohort Study to Investigate the Incidence of Cachexia During Chemotherapy in Patients with Colorectal Cancer. Adv Ther 2020;37:5010-22. [PMID: 33067699 DOI: 10.1007/s12325-020-01516-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 42 |
Huiskamp LFJ, Chargi N, Devriese LA, May AM, Huitema ADR, de Bree R. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis. J Clin Med 2020;9:E3780. [PMID: 33238530 DOI: 10.3390/jcm9113780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 43 |
Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM. Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options? Clin Pharmacol Ther 2021;109:591-604. [PMID: 33020924 DOI: 10.1002/cpt.2069] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 44 |
Rinninella E, Cintoni M, Raoul P, Pozzo C, Strippoli A, Ponziani FR, Pompili M, Bria E, Tortora G, Gasbarrini A, Mele MC. Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. Nutrients 2020;12:E3101. [PMID: 33053632 DOI: 10.3390/nu12103101] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 45 |
Biswas AK, Acharyya S. The Etiology and Impact of Muscle Wasting in Metastatic Cancer. Cold Spring Harb Perspect Med 2020;10:a037416. [PMID: 31615873 DOI: 10.1101/cshperspect.a037416] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 46 |
Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle 2020;11:366-80. [PMID: 31916411 DOI: 10.1002/jcsm.12525] [Cited by in Crossref: 140] [Cited by in F6Publishing: 121] [Article Influence: 46.7] [Reference Citation Analysis]
|
| 47 |
Burtin C, Bezuidenhout J, Sanders KJC, Dingemans AC, Schols AMWJ, Peeters STH, Spruit MA, De Ruysscher DKM. Handgrip weakness, low fat-free mass, and overall survival in non-small cell lung cancer treated with curative-intent radiotherapy. J Cachexia Sarcopenia Muscle 2020;11:424-31. [PMID: 32045108 DOI: 10.1002/jcsm.12526] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 48 |
Chung E, Lee HS, Cho ES, Park EJ, Baik SH, Lee KY, Kang J. Changes in Body Composition During Adjuvant FOLFOX Chemotherapy and Overall Survival in Non-Metastatic Colon Cancer. Cancers (Basel) 2019;12:E60. [PMID: 31878325 DOI: 10.3390/cancers12010060] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 49 |
Kurk SA, Stellato RK, Peeters PHM, Dorresteijn B, Jourdan M, Oskam MJ, Punt CJA, Koopman M, May AM. Trajectory of body mass and skeletal muscle indices and disease progression in metastatic colorectal cancer patients. Am J Clin Nutr 2019;110:1395-403. [PMID: 31515555 DOI: 10.1093/ajcn/nqz209] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 50 |
Ose J, Gigic B, Lin T, Liesenfeld DB, Böhm J, Nattenmüller J, Scherer D, Zielske L, Schrotz-King P, Habermann N, Ochs-Balcom HM, Peoples AR, Hardikar S, Li CI, Shibata D, Figueiredo J, Toriola AT, Siegel EM, Schmit S, Schneider M, Ulrich A, Kauczor HU, Ulrich CM. Multiplatform Urinary Metabolomics Profiling to Discriminate Cachectic from Non-Cachectic Colorectal Cancer Patients: Pilot Results from the ColoCare Study. Metabolites 2019;9:E178. [PMID: 31500101 DOI: 10.3390/metabo9090178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 51 |
Kurk S, Peeters P, Stellato R, Dorresteijn B, de Jong P, Jourdan M, Creemers GJ, Erdkamp F, de Jongh F, Kint P, Simkens L, Tanis B, Tjin-A-Ton M, Van Der Velden A, Punt C, Koopman M, May A. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle 2019;10:803-13. [PMID: 31094083 DOI: 10.1002/jcsm.12436] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
|
